Phaseline

Companies › Biofabri

Biofabri: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MTBVAC
Attenuated M. tuberculosis vaccine with deletions in phoP and fadD26 genes
–Phase 3TuberculosisFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04975178MTBVACPhase 3TuberculosisInfectious diseaseFeb 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Chengdu CoenBiotech Vedanta Biosciences Novavax Valneva Austria Osivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.